Wixom, MI, United States
Wixom, MI, United States

Time filter

Source Type

ST. LOUIS, Feb. 20, 2017 /PRNewswire/ -- Concordance Healthcare Solutions LLC, one of the largest, independent, healthcare distributors in the U.S., today announced the signing of a definitive agreement to acquire Rockwell Medical Supply. By adding this business, Concordance will now have...


Wiseguyreports.Com Adds “Nephrology and Urology Devices -Market Demand, Growth, Opportunities and analysis of Top Key Player Forecast to 2021” To Its Research Database According to Stratistics MRC, the Global Nephrology and Urology Devices is valued at $17.28 billion in 2015 and is expected to grow at a CAGR of 7.2% to reach $28.27 billion by 2022. Rising occurrence of chronic kidney diseases, increased spending on healthcare among the emerging regions and growing aged population across the world are some of the factors favoring the market growth. Moreover, the growing awareness about the benefits of these devices such as abridged recovery and treatment time is also propelling the global market. On the other hand, the high cost linked with these devices hampers the market. Dialysis devices commanded the largest market share and BPH treatment devices are anticipated to witness the fastest growth during the forecast period. Fresenius was leading the market in dialysis devices followed Baxter Corporation. Benign Prostatic Hyperplasia is a major concern and is expected to affect around 75% of male over the age of 55, thus driving the market to grow. Regionally, Europe is presently leading the market owing to the increasing need to keep up with the infrastructural requirements in hospital in region. Asia-Pacific is expected to grow at a faster pace due to the promising medical tourism industry in the region. New Product launch, merger and acquisition, and research and development are the successful strategies followed by the players in the market to gain the traction. Some of the key players in global Nephrology and Urology Devices market are Nikkiso Co. Ltd., Boston Scientific, American Medical Systems, LLC, Cook Medical, Olympus Medical Systems, Asahi Kasei Corporation, Rockwell Medical Technologies Inc., Dornier MedTech, Coloplast, Terumo Corporation, Fresenius Medical Care, B Braun Group, Nipro Corporation, Baxter International Inc., NxStage Medical, Inc. and C. R. Bard, Inc.,. Type of Diseases Covered: • Urinary Incontinence (UI) and Pelvic Organ Prolapsed (POP) o Incontinence Products o Interventional Therapies • Urinary Stone o Open Surgery o Percutaneous Nephrostolithotomy (PCNL) o Laser Lithotripsy o Extra-Corporeal Shock Wave Lithotripsy (ESWL) • Benign Prostatic Hyperplasia (BPH) o Holmium Laser Enucleation of Prostate (HOLEP) o Transurethral Radio Frequency Needle Ablation of the Prostate (TUNA) o Stenting (Prostatic Stents) o Surgery for BPH o Catheterization o Transurethral Microwave Thermotherapy of the Prostate (TUMT) • Chronic Kidney Disease And Renal Failure o Hemodialysis o Kidney Transplant o Peritoneal Dialysis Regions Covered: • North America o US o Canada o Mexico • Europe o Germany o France o Italy o UK o Spain o Rest of Europe • Asia Pacific o Japan o China o India o Australia o New Zealand o Rest of Asia Pacific What our report offers: - Market share assessments for the regional and country level segments - Market share analysis of the top industry players - Strategic recommendations for the new entrants - Market forecasts for a minimum of 7 years of all the mentioned segments, sub segments and the regional markets - Market Trends (Drivers, Constraints, Opportunities, Threats, Challenges, Investment Opportunities, and recommendations) - Strategic recommendations in key business segments based on the market estimations - Competitive landscaping mapping the key common trends - Company profiling with detailed strategies, financials, and recent developments - Supply chain trends mapping the latest technological advancements 4 Porters Five Force Analysis 4.1 Bargaining power of suppliers 4.2 Bargaining power of buyers 4.3 Threat of substitutes 4.4 Threat of new entrants 4.5 Competitive rivalry For more information, please visit https://www.wiseguyreports.com/sample-request/562724-nephrology-and-urology-devices-global-market-outlook-2015-2022


WiseGuyReports.Com Publish a New Market Research Report On –“Nephrology and Urology Devices Market Global Potential Growth,Share,Demand and Analysis Of Key Players Research Report Forecasts to 2022”. According to Researcher, the Global Nephrology and Urology Devices is valued at $17.28 billion in 2015 and is expected to grow at a CAGR of 7.2% to reach $28.27 billion by 2022. Rising occurrence of chronic kidney diseases, increased spending on healthcare among the emerging regions and growing aged population across the world are some of the factors favoring the market growth. Moreover, the growing awareness about the benefits of these devices such as abridged recovery and treatment time is also propelling the global market. On the other hand, the high cost linked with these devices hampers the market. For more information or any query mail at [email protected] Dialysis devices commanded the largest market share and BPH treatment devices are anticipated to witness the fastest growth during the forecast period. Fresenius was leading the market in dialysis devices followed Baxter Corporation. Benign Prostatic Hyperplasia is a major concern and is expected to affect around 75% of male over the age of 55, thus driving the market to grow. Regionally, Europe is presently leading the market owing to the increasing need to keep up with the infrastructural requirements in hospital in region. Asia-Pacific is expected to grow at a faster pace due to the promising medical tourism industry in the region. New Product launch, merger and acquisition, and research and development are the successful strategies followed by the players in the market to gain the traction. Some of the key players in global Nephrology and Urology Devices market are Nikkiso Co. Ltd., Boston Scientific, American Medical Systems, LLC, Cook Medical, Olympus Medical Systems, Asahi Kasei Corporation, Rockwell Medical Technologies Inc., Dornier MedTech, Coloplast, Terumo Corporation, Fresenius Medical Care, B Braun Group, Nipro Corporation, Baxter International Inc., NxStage Medical, Inc. and C. R. Bard, Inc.,. Type of Diseases Covered:  • Urinary Incontinence (UI) and Pelvic Organ Prolapsed (POP)  o Incontinence Products  o Interventional Therapies  • Urinary Stone  o Open Surgery  o Percutaneous Nephrostolithotomy (PCNL)  o Laser Lithotripsy  o Extra-Corporeal Shock Wave Lithotripsy (ESWL)  • Benign Prostatic Hyperplasia (BPH)  o Holmium Laser Enucleation of Prostate (HOLEP)  o Transurethral Radio Frequency Needle Ablation of the Prostate (TUNA)  o Stenting (Prostatic Stents)  o Surgery for BPH  o Catheterization  o Transurethral Microwave Thermotherapy of the Prostate (TUMT)  • Chronic Kidney Disease And Renal Failure  o Hemodialysis  o Kidney Transplant  o Peritoneal Dialysis Regions Covered:  • North America  o US  o Canada  o Mexico  • Europe  o Germany  o France  o Italy  o UK  o Spain  o Rest of Europe  • Asia Pacific  o Japan  o China  o India  o Australia  o New Zealand  o Rest of Asia Pacific  • Rest of the World  o Middle East  o Brazil  o Argentina  o South Africa  o Egypt What our report offers:  - Market share assessments for the regional and country level segments  - Market share analysis of the top industry players  - Strategic recommendations for the new entrants  - Market forecasts for a minimum of 7 years of all the mentioned segments, sub segments and the regional markets  - Market Trends (Drivers, Constraints, Opportunities, Threats, Challenges, Investment Opportunities, and recommendations)  - Strategic recommendations in key business segments based on the market estimations  - Competitive landscaping mapping the key common trends  - Company profiling with detailed strategies, financials, and recent developments  - Supply chain trends mapping the latest technological advancements 1 Executive Summary  2 Preface  2.1 Abstract  2.2 Stake Holders  2.3 Research Scope  2.4 Research Methodology  2.4.1 Data Mining  2.4.2 Data Analysis  2.4.3 Data Validation  2.4.4 Research Approach  2.5 Research Sources  2.5.1 Primary Research Sources  2.5.2 Secondary Research Sources  2.5.3 Assumptions  3 Market Trend Analysis  3.1 Introduction  3.2 Drivers  3.3 Restraints  3.4 Opportunities  3.5 Threats  3.6 Product Analysis  3.7 End User Analysis  3.8 Emerging Markets  4 Porters Five Force Analysis  4.1 Bargaining power of suppliers  4.2 Bargaining power of buyers  4.3 Threat of substitutes  4.4 Threat of new entrants  4.5 Competitive rivalry  5 Global Nephrology and Urology Devices Market, By Product  5.1 Introduction  5.2 Benign Prostatic Hyperplasia Devices  5.3 Urinary Stone Treatment  5.4 Prostate Cancer  5.5 Urinary Incontinence Devices  5.5.1 UI–Bulking  5.5.2 UI–Slings  5.6 Urological Endoscopes  5.7 Urological Catheters  5.8 Dialysis Devices  5.9 Erectile Dysfunction Device  5.10 Nephrostomy  5.11 Pelvic Floor Repair  5.12 Ureteral Access Devices  5.13 Endoscopy Devices  6 Global Nephrology and Urology Devices Market, By Disease Type  6.1 Introduction  6.2 Urinary Incontinence (UI) and Pelvic Organ Prolapsed (POP)  6.2.1 Incontinence Products  6.2.2 Interventional Therapies  6.3 Urinary Stone  6.3.1 Open Surgery  6.3.2 Percutaneous Nephrostolithotomy (PCNL)  6.3.3 Laser Lithotripsy  6.3.4 Extra-Corporeal Shock Wave Lithotripsy (ESWL)  6.4 Benign Prostatic Hyperplasia (BPH)  6.4.1 Holmium Laser Enucleation of Prostate (HOLEP)  6.4.2 Transurethral Radio Frequency Needle Ablation of the Prostate (TUNA)  6.4.3 Stenting (Prostatic Stents)  6.4.4 Surgery for BPH  6.4.5 Catheterization  6.4.6 Transurethral Microwave Thermotherapy of the Prostate (TUMT)  6.5 Chronic Kidney Disease And Renal Failure  6.5.1 Hemodialysis  6.5.2 Kidney Transplant  6.5.3 Peritoneal Dialysis For more information or any query mail at [email protected] Wise Guy Reports is part of the Wise Guy Consultants Pvt. Ltd. and offers premium progressive statistical surveying, market research reports, analysis & forecast data for industries and governments around the globe. Wise Guy Reports features an exhaustive list of market research reports from hundreds of publishers worldwide. We boast a database spanning virtually every market category and an even more comprehensive collection of market research reports under these categories and sub-categories.


News Article | November 7, 2016
Site: globenewswire.com

WIXOM, Mich., Nov. 07, 2016 (GLOBE NEWSWIRE) -- Rockwell Medical, Inc. (NASDAQ:RMTI), a fully-integrated biopharmaceutical company targeting end-stage renal disease (ESRD) and chronic kidney disease (CKD) with innovative products and services for the treatment of iron replacement, secondary hyperparathyroidism and hemodialysis, reported results for the third quarter of 2016. Mr. Robert L. Chioini, Chairman and Chief Executive Officer of Rockwell stated, “We continue to make solid progress in our efforts to obtain transitional add-on reimbursement for Triferic. We believe we are moving closer to our goal of securing it. Multiple stakeholders have aided us and support add-on reimbursement for Triferic. Concurrently, we have been educating our customers and patients about Triferic and its unique benefits. We also have advanced Triferic clinical development work for the renal application outside the U.S. as well as additional therapeutic indications. Overall, we are pleased with our progress, which includes ensuring we have redundancy in our manufacturing and supply capability.” Conference Call Information Rockwell Medical will be hosting a conference call to review its second quarter 2016 results on Monday, November 7, 2016 at 4:30 pm ET.  Investors are encouraged to call a few minutes in advance at (877)-857-6150, or for international callers (719)325-4825, passcode # 8926063 or to listen to the call via webcast at the Rockwell Medical IR web page:  http://ir.rockwellmed.com/ About Triferic Triferic is the only FDA approved drug indicated to replace iron and maintain hemoglobin in hemodialysis patients suffering from anemia. Via dialysate during each dialysis treatment, Triferic replaces the 5-7 mg iron loss that occurs in all patients, effectively maintaining their iron balance. Unlike IV iron products, Triferic binds iron immediately and completely to transferrin (carrier of iron in the body) upon entering the blood and it is then transported directly to the bone marrow to be incorporated into hemoglobin, with no increase in ferritin (stored iron and inflammation) and no anaphylaxis, addressing a significant unmet need in overcoming Functional Iron Deficiency (FID) in ESRD patients. Please visit www.triferic.com to view the Triferic mode-of-action (MOA) video and for more information. About Rockwell Medical Rockwell Medical is a fully-integrated biopharmaceutical company targeting end-stage renal disease (ESRD) and chronic kidney disease (CKD) with innovative products and services for the treatment of iron replacement, secondary hyperparathyroidism and hemodialysis. Rockwell’s recent FDA approved drug Triferic is indicated for iron replacement and maintenance of hemoglobin in hemodialysis patients. Triferic delivers iron to patients during their regular dialysis treatment, using dialysate as the delivery mechanism. Triferic has demonstrated that it safely and effectively delivers sufficient iron to the bone marrow and maintains hemoglobin, without increasing iron stores (ferritin). Rockwell intends to market Triferic to hemodialysis patients in the U.S. dialysis market and globally. Rockwell’s FDA approved generic drug Calcitriol is for treating secondary hyperparathyroidism in dialysis patients. Calcitriol (active vitamin D) injection is indicated in the management of hypocalcemia in patients undergoing chronic renal dialysis. It has been shown to significantly reduce elevated parathyroid hormone levels. Reduction of PTH has been shown to result in an improvement in renal osteodystrophy.  Rockwell intends to market Calcitriol to hemodialysis patients in the U.S. dialysis market. Rockwell is also an established manufacturer and leader in delivering high-quality hemodialysis concentrates/dialysates to dialysis providers and distributors in the U.S. and abroad. As one of the two major suppliers in the U.S., Rockwell’s products are used to maintain human life by removing toxins and replacing critical nutrients in the dialysis patient’s bloodstream. Rockwell has three U.S. manufacturing/distribution facilities. Rockwell’s exclusive renal drug therapies support disease management initiatives to improve the quality of life and care of dialysis patients and are intended to deliver safe and effective therapy, while decreasing drug administration costs and improving patient convenience. Rockwell Medical is developing a pipeline of drug therapies, including extensions of Triferic for indications outside of hemodialysis. Please visit www.rockwellmed.com for more information. Certain statements in this press release constitute "forward-looking statements" within the meaning of the federal securities laws, including, but not limited to, Rockwell’s intention to sell and market Calcitriol and Triferic. Words such as “may,” “might,” “will,” “should,” “believe,” “expect,” “anticipate,” “estimate,” “continue,” “predict,” “forecast,” “project,” “plan”, “intend” or similar expressions, or statements regarding intent, belief, or current expectations, are forward-looking statements. While Rockwell Medical believes these forward-looking statements are reasonable, undue reliance should not be placed on any such forward-looking statements, which are based on information available to us on the date of this release. These forward looking statements are based upon current estimates and assumptions and are subject to various risks and uncertainties, including without limitation those set forth in Rockwell Medical’s SEC filings. Thus, actual results could be materially different. Rockwell Medical expressly disclaims any obligation to update or alter statements whether as a result of new information, future events or otherwise, except as required by law. Triferic® is a registered trademark of Rockwell Medical, Inc.


News Article | November 4, 2016
Site: www.newsmaker.com.au

Global Renal Dialysis Equipment Market was valued at $14.5 billion in 2015 and is projected to reach $22.8 billion by 2022 at a Compound Annual Growth Rate of 6.7%. Growing aged population, a rising prevalence of diabetes and hypertension, End-Stage Renal Disease (ESRD) and lack of kidney donors for transplantation are some of the key factors contributing for the market growth. Furthermore, market has witnessed perceptible growth over the last five years owing to continued efforts made by governments to offer enhanced healthcare for people suffering from renal failure. However, lack of awareness about kidney disease and reimbursement issues in dialysis centers act as major constraints for this market. Peritoneal Dialysis (PD) has gained traction across various countries and now accounts for more than 10% of the dialysis procedures worldwide. By geography, North America and Europe are the largest markets owing to improved healthcare facilities and high frequency of kidney diseases in this region. However, Asia pacific is anticipated to grow at a faster pace due to growing investments in R&D coupled with increasing funding by government. India and China are projected to be the fastest-growing countries for kidney dialysis equipment market in Asia. Some of the key players in the market include Baxter International Inc., Nipro Corporation, Nikkiso, B. Braun Melsungen, Fresenius Medical Care Ag & Co., Asahi Kasei Corporation, Gambro, Allmed Medical, Bellco Societa Unipersonale, Fresenius Medical Care, Davita, Medivators, NXSTAGE Medical, Toray Industries and Rockwell Medical. Products Covered:  • Peritoneal Dialysis Solutions  o Intermittent Peritoneal Dialysis  o Continuous Cycling Peritoneal Dialysis (CCPD)  o Continuous Ambulatory Peritoneal Dialysis (CAPD)  • Hemodialysis Machines  o Blood Access Device Dialysate  o Dialyzers (Artificial Kidney)  o Hemodialysis Machines  • Dialysis Accessories  o Dialyzers  o AV Fistula Needles  o Dialysis Catheters  o Blood Tubing Sets  • Continuous Renal Replacement Therapy (CRRT) Machines  o Continuous Venovenous Hemodiafiltration (CVVHDF)  o Continuous Venovenous Hemofiltration (CVVH)  o Continuous Venovenous Hemodialysis (CVVHD)  o Slow, Continuous Ultrafiltration  Regions Covered:  • North America  o US  o Canada  o Mexico  • Europe  o Germany  o France  o Italy  o UK  o Spain  o Rest of Europe  • Asia Pacific  o Japan  o China  o India  o Australia  o New Zealand  o Rest of Asia Pacific  • Rest of the World  o Middle East  o Brazil  o Argentina  o South Africa  o Egypt What our report offers:  - Market share assessments for the regional and country level segments  - Market share analysis of the top industry players  - Strategic recommendations for the new entrants  - Market forecasts for a minimum of 7 years of all the mentioned segments, sub segments and the regional markets  - Market Trends (Drivers, Constraints, Opportunities, Threats, Challenges, Investment Opportunities, and recommendations)  - Strategic recommendations in key business segments based on the market estimations  - Competitive landscaping mapping the key common trends  - Company profiling with detailed strategies, financials, and recent developments  - Supply chain trends mapping the latest technological advancements Wise Guy Reports is part of the Wise Guy Consultants Pvt. Ltd. and offers premium progressive statistical surveying, market research reports, analysis & forecast data for industries and governments around the globe. Wise Guy Reports understand how essential statistical surveying information is for your organization or association. Therefore, we have associated with the top publishers and research firms all specialized in specific domains, ensuring you will receive the most reliable and up to date research data available.


News Article | December 8, 2016
Site: marketersmedia.com

LONDON, UK / ACCESSWIRE / December 8, 2016 / Active Wall St. blog coverage looks at the headline from Pfizer Inc. (NYSE: PFE). US lawmakers and politicians have waged a war against drug companies over high prices. In Britain, a similar move was observed, when on December 07, 2016, UK's antitrust regulator, Competition, and Markets Authority (CMA) slapped out a record $107 million fine against Pfizer. Register with us now for your free membership and blog access at: http://www.activewallst.com/register/. One of Pfizer's competitors within the Drug Manufacturers - Major space, Rockwell Medical, Inc. (NASDAQ: RMTI), reported on November 07, 2016, its results for the third quarter of 2016. AWS will be initiating a research report on Rockwell Medical in the coming days. Today, AWS is promoting its blog coverage on PFE; touching on RMTI. Get all of our free blog coverage and more by clicking on the links below: The charges stated that Pfizer overcharged the national health-care system for an epilepsy treatment. As per initial reports expenses for the national health-care system for epilepsy treatments amounted to £2 million in 2012, but after the price hike, it had to shell out £50 million in 2013. Phenytoin is an antiepileptic drug, primarily used to prevent and control seizures. Also known as an anticonvulsant, this drug is used to reduce the spread of seizure activity in the brain. It is also used to treat certain forms of irregular heartbeats. Pfizer sold the drug to UK wholesalers and pharmacies initially, under the brand name, 'Epanutin'. However, the drug was deliberately de-branded in September 2012, according to the accusation made by the CMA. Pfizer sold the UK distribution rights to Flynn Pharma in September 2012, which de-branded (or genericized) the drug, and was thus out of the price regulation rules. Flynn and Pfizer, according to CMA, utilized the loophole in UK's drug price regulation rules where drug manufacturers are free to set the prices for generic solutions. On August 07, 2015, the first accusation took to headlines when CMA alleged that the US drug maker, Pfizer, along with Flynn Pharma, deliberately charged excessive and unfair prices for phenytoin sodium capsules. The CMA stated that the prices rose from £2.83 to £67.50 after the rights were sold to Flynn. The prices were reduced marginally in May 2014, to £54. Ann Pope, the CMA's senior director of antitrust enforcement, said the prices were "very high compared to those previously charged" and had led to a big increase in the drug bill for the UK National Health Service. In a response to the accusation, a spokeswoman from Pfizer stated that before the deal with Flynn, it had incurred losses while selling Epanutin in the UK. The discontinuation of the drug, she said would have cost higher to the NHS. "Ensuring a sustainable supply of our products to UK patients is of paramount importance to Pfizer and was at the heart of our decision to divest the product," Pfizer's spokesperson stated. Since 2012, Pfizer supplied its product, phenytoin sodium capsules to Flynn Pharma, at prices between 780% and 1600% higher than the previous prices for Epanutin. Flynn further raised the prices by 2300% to 2600% from the initial price before supplying them to wholesalers and distributors. The CMA, in its latest findings, stated that both the entities, which held a dominant position in their respective segments for manufacturing and supplying the drug, raised the prices deliberately owing to monopolistic competition. Philip Marsden, the Chairman of the Case Decision Group released a three-point note for the CMA's investigation. Summarizing it, he stated, that the companies deliberately exploited the opportunity offered by de-branding to hike the prices for the drug which is used by more than 50,000 patients in the UK alone. He put light on the fact that phenytoin sodium capsules are a very old drug and there had been no recent innovation or significant investment, thus, the price raise was not justified. A spokesperson from Pfizer claimed that it was incurring loss prior to de-branding. However, according to CMA's calculations, any such loss would have been easily recovered within 2 months of the price hike. On Wednesday December 07, 2016, Pfizer's shares fell 1.17% from the previous closing price of $31.56, finishing the day at $31.19. A total volume of 44.02 million shares were exchanged for the day, which was higher than the average volume of 24.54 million over 3 months. For the last month, the stock has gained 3.69%. Furthermore, on a year to date basis, the stock gained 0.28%. The company's shares are trading at a PE ratio of 31.13 and have a dividend yield of 3.85%. Active Wall Street (AWS) produces regular sponsored and non-sponsored reports, articles, stock market blogs, and popular investment newsletters covering equities listed on NYSE and NASDAQ and micro-cap stocks. AWS has two distinct and independent departments. One department produces non-sponsored analyst certified content generally in the form of press releases, articles and reports covering equities listed on NYSE and NASDAQ and the other produces sponsored content (in most cases not reviewed by a registered analyst), which typically consists of compensated investment newsletters, articles and reports covering listed stocks and micro-caps. Such sponsored content is outside the scope of procedures detailed below. AWS has not been compensated; directly or indirectly; for producing or publishing this document. The non-sponsored content contained herein has been prepared by a writer (the "Author") and is fact checked and reviewed by a third party research service company (the "Reviewer") represented by a credentialed financial analyst, for further information on analyst credentials, please email info@activewallst.com. Rohit Tuli, a CFA® charterholder (the "Sponsor"), provides necessary guidance in preparing the document templates. The Reviewer has reviewed and revised the content, as necessary, based on publicly available information which is believed to be reliable. Content is researched, written and reviewed on a reasonable-effort basis. The Reviewer has not performed any independent investigations or forensic audits to validate the information herein. The Reviewer has only independently reviewed the information provided by the Author according to the procedures outlined by AWS. AWS is not entitled to veto or interfere in the application of such procedures by the third-party research service company to the articles, documents or reports, as the case may be. Unless otherwise noted, any content outside of this document has no association with the Author or the Reviewer in any way. AWS, the Author, and the Reviewer are not responsible for any error which may be occasioned at the time of printing of this document or any error, mistake or shortcoming. No liability is accepted whatsoever for any direct, indirect or consequential loss arising from the use of this document. AWS, the Author, and the Reviewer expressly disclaim any fiduciary responsibility or liability for any consequences, financial or otherwise arising from any reliance placed on the information in this document. Additionally, AWS, the Author, and the Reviewer do not (1) guarantee the accuracy, timeliness, completeness or correct sequencing of the information, or (2) warrant any results from use of the information. The included information is subject to change without notice. This document is not intended as an offering, recommendation, or a solicitation of an offer to buy or sell the securities mentioned or discussed, and is to be used for informational purposes only. Please read all associated disclosures and disclaimers in full before investing. Neither AWS nor any party affiliated with us is a registered investment adviser or broker-dealer with any agency or in any jurisdiction whatsoever. To download our report(s), read our disclosures, or for more information, visit http://www.activewallst.com/disclaimer/. For any questions, inquiries, or comments reach out to us directly. If you're a company we are covering and wish to no longer feature on our coverage list contact us via email and/or phone between 09:30 EDT to 16:00 EDT from Monday to Friday at: CFA® and Chartered Financial Analyst® are registered trademarks owned by CFA Institute. LONDON, UK / ACCESSWIRE / December 8, 2016 / Active Wall St. blog coverage looks at the headline from Pfizer Inc. (NYSE: PFE). US lawmakers and politicians have waged a war against drug companies over high prices. In Britain, a similar move was observed, when on December 07, 2016, UK's antitrust regulator, Competition, and Markets Authority (CMA) slapped out a record $107 million fine against Pfizer. Register with us now for your free membership and blog access at: http://www.activewallst.com/register/. One of Pfizer's competitors within the Drug Manufacturers - Major space, Rockwell Medical, Inc. (NASDAQ: RMTI), reported on November 07, 2016, its results for the third quarter of 2016. AWS will be initiating a research report on Rockwell Medical in the coming days. Today, AWS is promoting its blog coverage on PFE; touching on RMTI. Get all of our free blog coverage and more by clicking on the links below: The charges stated that Pfizer overcharged the national health-care system for an epilepsy treatment. As per initial reports expenses for the national health-care system for epilepsy treatments amounted to £2 million in 2012, but after the price hike, it had to shell out £50 million in 2013. Phenytoin is an antiepileptic drug, primarily used to prevent and control seizures. Also known as an anticonvulsant, this drug is used to reduce the spread of seizure activity in the brain. It is also used to treat certain forms of irregular heartbeats. Pfizer sold the drug to UK wholesalers and pharmacies initially, under the brand name, 'Epanutin'. However, the drug was deliberately de-branded in September 2012, according to the accusation made by the CMA. Pfizer sold the UK distribution rights to Flynn Pharma in September 2012, which de-branded (or genericized) the drug, and was thus out of the price regulation rules. Flynn and Pfizer, according to CMA, utilized the loophole in UK's drug price regulation rules where drug manufacturers are free to set the prices for generic solutions. On August 07, 2015, the first accusation took to headlines when CMA alleged that the US drug maker, Pfizer, along with Flynn Pharma, deliberately charged excessive and unfair prices for phenytoin sodium capsules. The CMA stated that the prices rose from £2.83 to £67.50 after the rights were sold to Flynn. The prices were reduced marginally in May 2014, to £54. Ann Pope, the CMA's senior director of antitrust enforcement, said the prices were "very high compared to those previously charged" and had led to a big increase in the drug bill for the UK National Health Service. In a response to the accusation, a spokeswoman from Pfizer stated that before the deal with Flynn, it had incurred losses while selling Epanutin in the UK. The discontinuation of the drug, she said would have cost higher to the NHS. "Ensuring a sustainable supply of our products to UK patients is of paramount importance to Pfizer and was at the heart of our decision to divest the product," Pfizer's spokesperson stated. Since 2012, Pfizer supplied its product, phenytoin sodium capsules to Flynn Pharma, at prices between 780% and 1600% higher than the previous prices for Epanutin. Flynn further raised the prices by 2300% to 2600% from the initial price before supplying them to wholesalers and distributors. The CMA, in its latest findings, stated that both the entities, which held a dominant position in their respective segments for manufacturing and supplying the drug, raised the prices deliberately owing to monopolistic competition. Philip Marsden, the Chairman of the Case Decision Group released a three-point note for the CMA's investigation. Summarizing it, he stated, that the companies deliberately exploited the opportunity offered by de-branding to hike the prices for the drug which is used by more than 50,000 patients in the UK alone. He put light on the fact that phenytoin sodium capsules are a very old drug and there had been no recent innovation or significant investment, thus, the price raise was not justified. A spokesperson from Pfizer claimed that it was incurring loss prior to de-branding. However, according to CMA's calculations, any such loss would have been easily recovered within 2 months of the price hike. On Wednesday December 07, 2016, Pfizer's shares fell 1.17% from the previous closing price of $31.56, finishing the day at $31.19. A total volume of 44.02 million shares were exchanged for the day, which was higher than the average volume of 24.54 million over 3 months. For the last month, the stock has gained 3.69%. Furthermore, on a year to date basis, the stock gained 0.28%. The company's shares are trading at a PE ratio of 31.13 and have a dividend yield of 3.85%. Active Wall Street (AWS) produces regular sponsored and non-sponsored reports, articles, stock market blogs, and popular investment newsletters covering equities listed on NYSE and NASDAQ and micro-cap stocks. AWS has two distinct and independent departments. One department produces non-sponsored analyst certified content generally in the form of press releases, articles and reports covering equities listed on NYSE and NASDAQ and the other produces sponsored content (in most cases not reviewed by a registered analyst), which typically consists of compensated investment newsletters, articles and reports covering listed stocks and micro-caps. Such sponsored content is outside the scope of procedures detailed below. AWS has not been compensated; directly or indirectly; for producing or publishing this document. The non-sponsored content contained herein has been prepared by a writer (the "Author") and is fact checked and reviewed by a third party research service company (the "Reviewer") represented by a credentialed financial analyst, for further information on analyst credentials, please email info@activewallst.com. Rohit Tuli, a CFA® charterholder (the "Sponsor"), provides necessary guidance in preparing the document templates. The Reviewer has reviewed and revised the content, as necessary, based on publicly available information which is believed to be reliable. Content is researched, written and reviewed on a reasonable-effort basis. The Reviewer has not performed any independent investigations or forensic audits to validate the information herein. The Reviewer has only independently reviewed the information provided by the Author according to the procedures outlined by AWS. AWS is not entitled to veto or interfere in the application of such procedures by the third-party research service company to the articles, documents or reports, as the case may be. Unless otherwise noted, any content outside of this document has no association with the Author or the Reviewer in any way. AWS, the Author, and the Reviewer are not responsible for any error which may be occasioned at the time of printing of this document or any error, mistake or shortcoming. No liability is accepted whatsoever for any direct, indirect or consequential loss arising from the use of this document. AWS, the Author, and the Reviewer expressly disclaim any fiduciary responsibility or liability for any consequences, financial or otherwise arising from any reliance placed on the information in this document. Additionally, AWS, the Author, and the Reviewer do not (1) guarantee the accuracy, timeliness, completeness or correct sequencing of the information, or (2) warrant any results from use of the information. The included information is subject to change without notice. This document is not intended as an offering, recommendation, or a solicitation of an offer to buy or sell the securities mentioned or discussed, and is to be used for informational purposes only. Please read all associated disclosures and disclaimers in full before investing. Neither AWS nor any party affiliated with us is a registered investment adviser or broker-dealer with any agency or in any jurisdiction whatsoever. To download our report(s), read our disclosures, or for more information, visit http://www.activewallst.com/disclaimer/. For any questions, inquiries, or comments reach out to us directly. If you're a company we are covering and wish to no longer feature on our coverage list contact us via email and/or phone between 09:30 EDT to 16:00 EDT from Monday to Friday at: CFA® and Chartered Financial Analyst® are registered trademarks owned by CFA Institute.


News Article | March 2, 2017
Site: globenewswire.com

WIXOM, Mich., March 02, 2017 (GLOBE NEWSWIRE) -- Rockwell Medical, Inc. (NASDAQ:RMTI), a fully-integrated biopharmaceutical company targeting end-stage renal disease (ESRD) and chronic kidney disease (CKD) with innovative products for the treatment of iron replacement, secondary hyperparathyroidism and hemodialysis, announced today that David Domzalski, has been nominated to join the Company’s Board of Directors. Mr. Domzalski is nominated to replace Mr. Ken Holt, whose term is expiring. Mr. Holt has served the Rockwell Board for several years and will remain engaged through the end of his term. “David has a proven track record at a senior level in the pharmaceutical industry,” said Robert L. Chioini, Founder, Chairman and CEO of Rockwell Medical. “He has extensive experience in building commercial organizations and launching products, which will be helpful as we commercialize Triferic globally. We are very pleased to have someone of David’s caliber join our Board of Directors and we look forward to the strategic contributions and insights he will bring.” Mr. Chioini also added, “Ken Holt has been a valuable member of our Board and served the Company loyally for many years and has contributed a great deal during his tenure. We thank Ken for his contributions and wish him the very best.” “I am excited to join the Rockwell Medical Board of Directors at this exciting time for the company,” said David Domzalski. “I look forward to working with the executive team and the Board and contributing to the successful launches of their drug products into the global marketplace.” David Domzalski is an accomplished healthcare and pharmaceutical executive with strategic and operational experience across key functional disciplines, including commercial operations, clinical development, manufacturing and product development, corporate financing, and business development. He has extensive experience in building and restructuring commercial organizations within multi-cultural environments of “start-up” and established corporations. He has a record of achievement in new product launches and life-cycle management across multiple therapeutic classes. He is highly successful in cultivating external partnerships and strategic alliances guided by strong interpersonal and negotiation skills. Mr. Domzalski has more than 20 years of industrial experience. David Domzalski currently serves as President of the U.S. subsidiary of Foamix Pharmaceuticals Inc., a position he has held since April 2014. Prior to his tenure at Foamix, Mr. Domzalski was Vice President of Sales & Marketing at LEO Pharma, Inc. where he led the efforts to design and build-out the U.S. commercial operations, overseeing approximately 200 employees across multiple functional areas. He successfully managed the turnaround of LEO Pharma’s psoriasis franchise from a 2-year prescription decline to an annual growth of 26%. He was responsible for the strategic re-launch of Taclonex® Topical Suspension, which resulted in Taclonex being reestablished as the number one brand in the category. Prior to LEO Pharma, Mr. Domzalski was the Senior Vice President and General Manager of the Women’s Health & Urology division of Azur Pharma, where he had full P&L responsibility for a start-up business unit. Before Azur, Mr. Domzalski spent 5 years from 2003 to 2008 as the Vice President of Sales & Marketing for Warner Chilcott, where he directed all commercial efforts for in-line brands focused on therapeutic areas of dermatology, women’s health and urology. His achievements at Warner Chilcott included the launch of four products within a twelve month period, including Taclonex for psoriasis and Doryx® Tablets for acne. He led the structural design, development and growth of the commercial team at Warner Chilcott from 150 to 500 employees. Earlier in his career, Mr. Domzalski held senior sales and marketing positions at Sanofi-Synthelabo, Pharmacia, Dendrite International and Parke-Davis. He earned a Bachelor of Arts in Economics and Political Science from Muhlenberg College. About Rockwell Medical Rockwell Medical is a fully-integrated biopharmaceutical company targeting end-stage renal disease (ESRD) and chronic kidney disease (CKD) with innovative products for the treatment of iron replacement, secondary hyperparathyroidism and hemodialysis. Rockwell’s anemia drug Triferic is the only FDA approved product indicated for iron replacement and maintenance of hemoglobin in hemodialysis patients. Triferic delivers iron to patients during their regular dialysis treatment, using dialysate as the delivery mechanism. Triferic has demonstrated that it safely and effectively delivers sufficient iron to the bone marrow and maintains hemoglobin, without increasing iron stores (ferritin). Rockwell intends to market Triferic to hemodialysis patients in the U.S. dialysis market and globally. Rockwell’s FDA approved generic drug Calcitriol is for treating secondary hyperparathyroidism in dialysis patients. Calcitriol (active vitamin D) injection is indicated in the management of hypocalcemia in patients undergoing chronic renal dialysis. It has been shown to significantly reduce elevated parathyroid hormone levels. Reduction of PTH has been shown to result in an improvement in renal osteodystrophy. Rockwell intends to market Calcitriol to hemodialysis patients in the U.S. dialysis market. Rockwell is also an established manufacturer and leader in delivering high-quality hemodialysis concentrates/dialysates to dialysis providers and distributors in the U.S. and abroad. As one of the two major suppliers in the U.S., Rockwell’s products are used to maintain human life by removing toxins and replacing critical nutrients in the dialysis patient’s bloodstream. Rockwell has three U.S. manufacturing/distribution facilities. Rockwell’s exclusive renal drug therapies support disease management initiatives to improve the quality of life and care of dialysis patients and are intended to deliver safe and effective therapy, while decreasing drug administration costs and improving patient convenience. Rockwell Medical is developing a pipeline of drug therapies, including extensions of Triferic for indications outside of hemodialysis. Please visit www.rockwellmed.com for more information. Certain statements in this press release constitute "forward-looking statements" within the meaning of the federal securities laws, including, but not limited to, Rockwell’s intention to sell and market Calcitriol and Triferic. Words such as “may,” “might,” “will,” “should,” “believe,” “expect,” “anticipate,” “estimate,” “continue,” “predict,” “forecast,” “project,” “plan,” “intend” or similar expressions, or statements regarding intent, belief, or current expectations, are forward-looking statements. While Rockwell Medical believes these forward-looking statements are reasonable, undue reliance should not be placed on any such forward-looking statements, which are based on information available to us on the date of this release. These forward-looking statements are based upon current estimates and assumptions and are subject to various risks and uncertainties, including without limitation those set forth in Rockwell Medical’s SEC filings. Thus, actual results could be materially different. Rockwell Medical expressly disclaims any obligation to update or alter statements whether as a result of new information, future events or otherwise, except as required by law. Triferic® is a registered trademark of Rockwell Medical, Inc.


JACKSON, Mich. & ST. LOUIS PARK, Minn.--(BUSINESS WIRE)--Richmond Brothers, Inc., a Michigan-based SEC registered investment advisor and wealth management firm that is the largest beneficial owner of Rockwell Medical, Inc. (NASDAQ: RMTI) (“Rockwell” or the “Company”), and Mark H. Ravich, who together with their affiliates beneficially own over 6.1 million shares, or 11.9% of the Company’s outstanding common stock, today announced the nomination of David S. Richmond and Mark H. Ravich for election to the Company’s Board of Directors (the “Board”) at the upcoming 2017 Annual Meeting of Shareholders (the “Annual Meeting”). David S. Richmond, Chairman of Richmond Brothers, Inc., and Mark H. Ravich issued the following statement: “As long-term holders of Rockwell Medical stock, we have been disappointed time and time again by the current Board and management’s repeated strategic failures and the poor corporate governance that we believe have plagued the Company for years. We have made multiple attempts over several years to engage constructively with Rockwell to discuss improvements to the Company’s strategic approach, execution and corporate governance – but we have been repeatedly rebuffed. Management and the Board have proven themselves to be strongly averse to shareholder friendly actions, have failed dismally to communicate with shareholders in a transparent and constructive manner and have been unable to effectively execute on strategies that would drive shareholder value. The fact that the Company’s compensation plan was voted down by shareholders at the 2016 Annual Meeting, coupled with the nearly 11 million votes withheld from the director then running for reelection, demonstrates, in our view, shareholders’ frustration. Unfortunately, management and the Board have failed to heed these signals of shareholder discontent and have persisted in running Rockwell as if it were a private company not accountable to the interests of public shareholders. Furthermore, we believe that with the right strategy and proper execution, Rockwell has the potential to increase significantly in value, especially if its new FDA-approved iron maintenance drug Triferic becomes the standard of care iron maintenance therapy for hemodialysis patients. In our view, the market does not yet understand Triferic’s opportunity worldwide for hemodialysis or the potential to develop Triferic as a platform drug for numerous other indications. Based on a model focused on just the dialysis market in the U.S. alone (i.e. not even the best case scenario), a recent analyst note from Craig-Hallum Capital Group suggests: ‘On a longer term basis, if Triferic advances towards a full commercial launch, we believe that revenue can exceed $300 million given the expected ramp in Triferic and Calcitriol. Applying a 7x revenue multiple would produce a ~$42 stock price.’1 The following represent some of the strategic missteps and corporate governance issues that have plagued Rockwell in recent years: Given this litany of issues, we believe that Rockwell is in desperate need of Board members who have the best interests of ALL of the Company’s shareholders at heart and who will be responsible stewards of shareholder value. We believe fresh, independent voices at the Board level would disrupt the culture of entrenchment and inaction that has characterized the Company’s governance to date and would have the potential to lead to further Board refreshment in the future. As large, long-term holders of Rockwell stock, we believe that we are very well-qualified to bring a truly shareholder-friendly perspective to the Company’s Board and push for the real change that is needed at the Company. We would also note that because the Company did not disclose which class recently-appointed director Robin L. Smith belongs to, it is unclear at this time whether one or two Board seats are up for election at the upcoming Annual Meeting. This ambiguity is yet another example of Rockwell’s failure to communicate transparently with shareholders. Richmond Brothers, Inc. is an SEC registered investment advisor and wealth management firm founded in 1994. Mark Ravich is a private investor and currently serves as President of Tri-Star Management, Inc., a commercial real estate management and syndication company that he co-founded in 1998. CERTAIN INFORMATION CONCERNING THE PARTICIPANTS Richmond Brothers, Inc. (“Richmond Brothers”) and Mark H. Ravich, together with the other participants named herein, intend to file a preliminary proxy statement and accompanying proxy card with the Securities and Exchange Commission (“SEC”) to be used to solicit votes for the election of their slate of highly-qualified director nominees at the 2017 annual meeting of shareholders of Rockwell Medical, Inc., a Michigan corporation (the “Company”). RICHMOND BROTHERS STRONGLY ADVISES ALL SHAREHOLDERS OF THE COMPANY TO READ THE PROXY STATEMENT AND OTHER PROXY MATERIALS AS THEY BECOME AVAILABLE BECAUSE THEY WILL CONTAIN IMPORTANT INFORMATION. SUCH PROXY MATERIALS WILL BE AVAILABLE AT NO CHARGE ON THE SEC’S WEB SITE AT HTTP://WWW.SEC.GOV. IN ADDITION, THE PARTICIPANTS IN THIS PROXY SOLICITATION WILL PROVIDE COPIES OF THE PROXY STATEMENT WITHOUT CHARGE, WHEN AVAILABLE, UPON REQUEST. The participants in the proxy solicitation are Norman J. Ravich Irrevocable Trust (“NJR Trust”), Norman and Sally Ravich Family Trust (“NSR Trust”), Alexander Coleman Ravich 1991 Irrevocable Trust (“ACR Trust”), Alyssa Danielle Ravich 1991 Irrevocable Trust (“ADR Trust”), Mark H. Ravich, Richmond Brothers, RBI Private Investment I, LLC (“RBI PI”), RBI PI Manager, LLC (“RBI Manager”), Richmond Brothers 401(k) Profit Sharing Plan (“RBI Plan”), David S. Richmond and Matthew J. Curfman. As of the date hereof, NJR Trust beneficially owned 44,400 shares of common stock, no par value per share (the “Common Stock”). As of the date hereof, NSR Trust beneficially owned 18,500 shares of Common Stock, consisting of shares underlying certain call options. As of the date hereof, ACR Trust beneficially owned 25,000 shares of Common Stock. As of the date hereof, ADR Trust beneficially owned 25,000 shares of Common Stock. As of the date hereof, Mr. Ravich directly beneficially owned 354,750 shares of Common Stock, including 70,000 shares underlying certain call options. Mr. Ravich, as the trustee of each of NJR Trust, NSR Trust, ACR Trust and ADR Trust, may be deemed to beneficially own the 112,900 shares beneficially owned in the aggregate by such trusts. As of the date hereof, 5,183,152 shares of Common Stock were held in certain accounts managed by Richmond Brothers (the “Separately Managed Accounts”). Richmond Brothers, as the investment advisor to the Separately Managed Accounts, may be deemed to beneficially own the 5,183,152 shares held in the Separately Managed Accounts. As of the date hereof, RBI PI beneficially owned 164,841 shares of Common Stock. RBI Manager, as the manager of RBI PI, may be deemed to beneficially own the 164,841 shares owned by RBI PI. As of the date hereof, RBI Plan beneficially owned 34,087 shares of Common Stock. As of the date hereof, Mr. Richmond beneficially owned directly 176,412 shares of Common Stock. Mr. Richmond, as Chairman of Richmond Brothers, manager of RBI Manager and a trustee of RBI Plan, may also be deemed to beneficially own the 5,183,152 shares held in the Separately Managed Accounts, 164,841 shares owned by RBI PI and 34,087 Shares owned by RBI Plan. Mr. Richmond may also be deemed to beneficially own the 28,096 shares owned directly by his spouse, 147 shares owned directly by his daughter and 7 shares owned directly by his son. As of the date hereof, Mr. Curfman beneficially owned directly 40,684 shares of Common Stock. Mr. Curfman, as President of Richmond Brothers and a trustee of RBI Plan, may also be deemed to beneficially own the 5,183,152 shares held in the Separately Managed Accounts and 34,087 Shares owned by RBI Plan. Mr. Curfman may also be deemed to beneficially own the 34,385 shares owned directly by his spouse.


News Article | February 21, 2017
Site: globenewswire.com

WIXOM, Mich., Feb. 21, 2017 (GLOBE NEWSWIRE) -- Rockwell Medical, Inc. (NASDAQ:RMTI), a fully-integrated biopharmaceutical company targeting end-stage renal disease (ESRD) and chronic kidney disease (CKD) with innovative products for the treatment of iron replacement, secondary hyperparathyroidism and hemodialysis, today provided an update on the commercial launch progress of Calcitriol, stating that the FDA has requested that the Company resubmit the application for the new contract manufacturer as a Prior Approval Supplement (PAS) and pay a fee for the Agency review. As a result, the Company anticipates Calcitriol to become commercially available in the U.S. market in approximately 4-6 months. Calcitriol is Rockwell’s FDA approved active Vitamin D injection for the management of hypocalcemia in patients undergoing chronic renal dialysis. Dr. Raymond Pratt, Chief Medical Officer of Rockwell stated, “Although we believe the initial submission contained all the information FDA required, we are complying with the Agency’s request in an effort to get Calcitriol into the market as fast as possible.” About Rockwell Medical Rockwell Medical is a fully-integrated biopharmaceutical company targeting end-stage renal disease (ESRD) and chronic kidney disease (CKD) with innovative products for the treatment of iron replacement, secondary hyperparathyroidism and hemodialysis. Rockwell’s anemia drug Triferic is the only FDA approved product indicated for iron replacement and maintenance of hemoglobin in hemodialysis patients. Triferic delivers iron to patients during their regular dialysis treatment, using dialysate as the delivery mechanism. Triferic has demonstrated that it safely and effectively delivers sufficient iron to the bone marrow and maintains hemoglobin, without increasing iron stores (ferritin). Rockwell intends to market Triferic to hemodialysis patients in the U.S. dialysis market and globally. Rockwell’s FDA approved generic drug Calcitriol is for treating secondary hyperparathyroidism in dialysis patients. Calcitriol (active vitamin D) injection is indicated in the management of hypocalcemia in patients undergoing chronic renal dialysis. It has been shown to significantly reduce elevated parathyroid hormone levels. Reduction of PTH has been shown to result in an improvement in renal osteodystrophy. Rockwell intends to market Calcitriol to hemodialysis patients in the U.S. dialysis market. Rockwell is also an established manufacturer and leader in delivering high-quality hemodialysis concentrates/dialysates to dialysis providers and distributors in the U.S. and abroad. As one of the two major suppliers in the U.S., Rockwell’s products are used to maintain human life by removing toxins and replacing critical nutrients in the dialysis patient’s bloodstream. Rockwell has three U.S. manufacturing/distribution facilities. Rockwell’s exclusive renal drug therapies support disease management initiatives to improve the quality of life and care of dialysis patients and are intended to deliver safe and effective therapy, while decreasing drug administration costs and improving patient convenience. Rockwell Medical is developing a pipeline of drug therapies, including extensions of Triferic for indications outside of hemodialysis. Please visit www.rockwellmed.com for more information. Certain statements in this press release constitute "forward-looking statements" within the meaning of the federal securities laws, including, but not limited to, Rockwell’s intention to sell and market Calcitriol and Triferic. Words such as “may,” “might,” “will,” “should,” “believe,” “expect,” “anticipate,” “estimate,” “continue,” “predict,” “forecast,” “project,” “plan”, “intend” or similar expressions, or statements regarding intent, belief, or current expectations, are forward-looking statements. While Rockwell Medical believes these forward-looking statements are reasonable, undue reliance should not be placed on any such forward-looking statements, which are based on information available to us on the date of this release. These forward-looking statements are based upon current estimates and assumptions and are subject to various risks and uncertainties, including without limitation those set forth in Rockwell Medical’s SEC filings. Thus, actual results could be materially different. Rockwell Medical expressly disclaims any obligation to update or alter statements whether as a result of new information, future events or otherwise, except as required by law. Triferic® is a registered trademark of Rockwell Medical, Inc.


The invention provides for methods of treating a dialysis patient that is hyporesponsive to erythropoietin stimulating agents (ESA) comprising administering soluble ferric triphosphate (SFP) composition and administering a dose of ESA that is significantly reduced compared to the dose of ESA required by a dialysis patient that is hyporesponsive to ESA that has not received SFP.

Loading Rockwell Medical collaborators
Loading Rockwell Medical collaborators